tiprankstipranks
Trending News
More News >
Aardvark Therapeutics, Inc. (AARD)
:AARD
US Market

Aardvark Therapeutics, Inc. (AARD) Stock Forecast & Price Target

Compare
12 Followers
See the Price Targets and Ratings of:

AARD Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Aardvark
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AARD Stock 12 Month Forecast

Average Price Target

$31.50
▲(319.44%Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Aardvark Therapeutics, Inc. in the last 3 months. The average price target is $31.50 with a high forecast of $50.00 and a low forecast of $21.00. The average price target represents a 319.44% change from the last price of $7.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.33,14.304615384615385,17.27923076923077,20.253846153846155,23.228461538461538,26.203076923076924,29.17769230769231,32.152307692307694,35.12692307692308,38.10153846153846,41.07615384615385,44.050769230769234,47.02538461538462,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.33,12.881538461538462,14.433076923076923,15.984615384615385,17.536153846153848,19.087692307692308,20.63923076923077,22.190769230769234,23.742307692307694,25.293846153846154,26.845384615384617,28.39692307692308,29.948461538461544,{"y":31.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.33,12.073846153846153,12.817692307692308,13.561538461538461,14.305384615384614,15.04923076923077,15.793076923076923,16.536923076923078,17.28076923076923,18.024615384615384,18.768461538461537,19.512307692307694,20.256153846153843,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.3,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$31.50Lowest Price Target$21.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on AARD
Brian AbrahamsRBC Capital
RBC Capital
$21
Buy
179.63%
Upside
Reiterated
03/31/25
RBC Capital Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)
Bank of America Securities Analyst forecast on AARD
Tim AndersonBank of America Securities
Bank of America Securities
$22$26
Buy
246.21%
Upside
Reiterated
03/27/25
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions
Cantor Fitzgerald Analyst forecast on AARD
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$50
Buy
565.78%
Upside
Initiated
03/10/25
Aardvark Therapeutics initiated with an Overweight at Cantor FitzgeraldAardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald
Morgan Stanley Analyst forecast on AARD
Michael UlzMorgan Stanley
Morgan Stanley
$29
Buy
286.15%
Upside
Initiated
03/10/25
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (NASDAQ: AARD) and Surgery Partners (NASDAQ: SGRY)We are initiating coverage of Aardvark Therapeutics with an Overweight rating and $29 price target.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on AARD
Brian AbrahamsRBC Capital
RBC Capital
$21
Buy
179.63%
Upside
Reiterated
03/31/25
RBC Capital Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)
Bank of America Securities Analyst forecast on AARD
Tim AndersonBank of America Securities
Bank of America Securities
$22$26
Buy
246.21%
Upside
Reiterated
03/27/25
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions
Cantor Fitzgerald Analyst forecast on AARD
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$50
Buy
565.78%
Upside
Initiated
03/10/25
Aardvark Therapeutics initiated with an Overweight at Cantor FitzgeraldAardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald
Morgan Stanley Analyst forecast on AARD
Michael UlzMorgan Stanley
Morgan Stanley
$29
Buy
286.15%
Upside
Initiated
03/10/25
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (NASDAQ: AARD) and Surgery Partners (NASDAQ: SGRY)We are initiating coverage of Aardvark Therapeutics with an Overweight rating and $29 price target.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aardvark Therapeutics, Inc.

1 Month
xxx
Success Rate
2/3 ratings generated profit
67%
Average Return
+11.23%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +11.23% per trade.
3 Months
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+29.90%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +29.90% per trade.
1 Year
Tim AndersonBank of America Securities
Success Rate
3/3 ratings generated profit
100%
Average Return
+27.80%
reiterated a buy rating last month
Copying Tim Anderson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +27.80% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+27.80%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +27.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AARD Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Strong Buy
7
9
12
Buy
0
0
0
Hold
0
0
0
Sell
0
0
0
Strong Sell
0
0
0
total
7
9
12
In the current month, AARD has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AARD average Analyst price target in the past 3 months is 31.50.
Each month's total comprises the sum of three months' worth of ratings.

AARD Financial Forecast

AARD Earnings Forecast

The previous quarter’s earnings for AARD were -$0.71.
The previous quarter’s earnings for AARD were -$0.71.

AARD Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

AARD Stock Forecast FAQ

What is AARD’s average 12-month price target, according to analysts?
Based on analyst ratings, Aardvark Therapeutics, Inc.’s 12-month average price target is 31.50.
    What is AARD’s upside potential, based on the analysts’ average price target?
    Aardvark Therapeutics, Inc. has 319.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AARD a Buy, Sell or Hold?
          Aardvark Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Aardvark Therapeutics, Inc.’s price target?
            The average price target for Aardvark Therapeutics, Inc. is 31.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $21.00. The average price target represents 319.44% Increase from the current price of $7.51.
              What do analysts say about Aardvark Therapeutics, Inc.?
              Aardvark Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of AARD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis